Table 3.
Preoperative variables in patients undergoing robotic pancreatoduodenectomy (RPD) with (RPD + HAA) and without (RPD − HAA) hepatic arterial anomalies
| RPD + HAA (n = 30) | RPD − HAA (n = 112) | P-value | |
|---|---|---|---|
| Patient demographics | |||
| Age, years, mean ± SD | 65.9 ± 12.7 | 67.7 ± 12.6 | 0.476 |
| Female, n (%) | 10 (33.3%) | 56 (50.0%) | 0.149 |
| BMI, kg/m2, mean ± SD | 27.3 ± 6.3 | 27.2 ± 5.4 | 0.945 |
| CCI age-adjusted, mean ± SD | 4.0 ± 2.3 | 4.1 ± 2.7 | 0.882 |
| CCI age-unadjusted, mean ± SD | 2.23 ± 1.4 | 2.02 ± 1.8 | 0.547 |
| Pathology, n (%) | |||
| Malignancy | 27 (90.0%) | 88 (78.6%) | 0.196 |
| Histology, n (%) | |||
| PDAC | 14 (46.7%) | 43 (38.4%) | 0.832 |
| Ampullary adenocarcinoma | 7 (23.3%) | 20 (17.9%) | |
| Cholangiocarcinoma | 4 (13.3%) | 5 (4.5%) | |
| IPMN | 3 (10.0%) | 16 (14.3%) | |
| Neuroendocrine tumour | 1 (3.3%) | 11 (9.8%) | |
| DCA | 0 | 4 (3.6%) | |
| GIST | 0 | 2 (1.8%) | |
| Others | 1a (3.3%) | 11 (9.8%) | |
a
Renal cancer metastasis.
BMI, body mass index; CCI, Charlson Comorbidity Index; DCA, duodenal adenocarcinoma; GIST, gastrointestinal stromal tumour; IPMN, intraductal papillary mucinous neoplasm; PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation.